



Dimitri Krainc, MD
Northwestern University
 Department of Neurology

AREA(S) OF FOCUS:

Defining the molecular pathways leading to nervous system degeneration

The Krainc lab focuses on understanding fundamental molecular mechanisms of neuronal function in health and disease.

KEY RESEARCH AREAS:

Parkinson's disease


Identify and interrupt the toxic signaling leading to neurodegeneration.

Personalized medicine

Investigate linkage between cell recycling systems & energy metabolism in preclinical human models of neurodegeneration.

Huntington's disease and Frontotemporal Dementia

Understand the biological mechanisms regulating neuronal death and protein degradation.



ENTREPRENEURIAL SUCCESS:



VANQUABIO

Vanqua BIO is developing innovative programs for treatment of neurodegenerative diseases.

The company has a unique screening platform that uses patient-induced pluripotent stem cells to develop neurological diseases therapies.

The pipeline includes:

- Small-molecule activators targeting the lipid recycling system in Parkinson's, Gauche disease, and Lewy Body Dementia
- Small molecules targeting the immune system for Alzheimer's, Parkinson's and peripheral diseases
- Novel therapies for neurodegenerative diseases

Series B (2021) - \$85M

Established at Fulton Labs.



CHICAGO BIOMEDICAL CONSORTIUM

